Other analysts also recently issued research reports about the stock. Credit Suisse Group set a GBX 1,860 ($22.89) target price on shares of GlaxoSmithKline and gave the company a neutral rating in a research report on Thursday, April 30th. Citigroup reissued a neutral rating on shares of GlaxoSmithKline in a research report on Wednesday, July 15th. Goldman Sachs Group set a GBX 2,060 ($25.35) target price on shares of GlaxoSmithKline and gave the company a buy rating in a research report on Wednesday, July 15th. Jefferies Financial Group reissued a buy rating on shares of GlaxoSmithKline in a research report on Monday, June 29th. Finally, Liberum Capital reissued a hold rating on shares of GlaxoSmithKline in a research report on Thursday, May 28th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of GBX 1,832.24 ($22.55).
Shares of LON GSK opened at GBX 1,529.80 ($18.83) on Wednesday. The company has a 50 day simple moving average of GBX 1,624 and a 200 day simple moving average of GBX 1,636.23. The firm has a market cap of $76.75 billion and a PE ratio of 14.30. GlaxoSmithKline has a 1 year low of GBX 16.27 ($0.20) and a 1 year high of GBX 1,857 ($22.85). The company has a debt-to-equity ratio of 159.26, a current ratio of 0.87 and a quick ratio of 0.54.
GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, July 29th. The company reported GBX 56.90 ($0.70) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that GlaxoSmithKline will post 11385.0001492 earnings per share for the current fiscal year.
The company also recently announced a dividend, which will be paid on Thursday, October 8th. Investors of record on Thursday, August 13th will be issued a GBX 19 ($0.23) dividend. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, August 13th. GlaxoSmithKline’s dividend payout ratio is currently 71.03%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading: How does new data get added to a blockchain?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.